Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42 40 . . . The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ42), total Tau (T-tau) and Tau phosphorylated at threonine 181 (P-tau181) have proven diagnostic accuracy for mild cognitive impairment and dementia due to Alzheimer’s Disease (AD) In an effort to improve the accuracy of an AD diagnosis, it is important to be able to distinguish between AD and other types of
Evaluation of CSF-tau and CSF-Aβ42 as Diagnostic Markers for Alzheimer . . . Objective To evaluate the diagnostic potential of cerebrospinal fluid (CSF) levels of tau and β-amyloid protein ending at amino acid 42 (Aβ42) as biomarkers for Alzheimer disease (AD) in clinical practice Design A 1-year prospective study Setting Community population–based sample of all consecutive patients admitted for investigation of cognitive symptoms to the Piteå River Valley
CSF and plasma Aβ42 40 across Alzheimer’s disease continuum: comparison . . . Objectives Decreased cerebrospinal fluid (CSF) amyloid beta 42 40 ratio (Aβ42 40) is one of the core Alzheimer’s disease (AD) biomarkers Measurement of Aβ42 40 in plasma has also been proposed as a surrogate marker for amyloidosis, however the validity and the diagnostic performance of this biomarker is still uncertain Here we evaluated two immunoassays targeting distinct regions of the
Neurochemical diagnosis of Alzheimer’s dementia by CSF Aβ42, Aβ42 Aβ40 . . . Neurochemical diagnosis of Alzheimer’s dementia by CSF Aβ42, Aβ42 Aβ40 ratio and total tau The increase in sensitivity, specificity and correct classification of patients when Aβ peptides ratio is applied instead of Aβ42 concentration alone is only a moderate one (e g correct discrimination of AD and controls increases from 86 7 to
Alzheimer Disease Cerebrospinal Fluid Biomarkers in a Tertiary . . . Area under the curve (AUC) of the p-Tau181 Aβ42 ratio is demonstrated (0 869), as are the specificity (0 889) and sensitivity (0 821) using the assay cutoff of >0 023 Bottom, The AUC, confidence interval, positive and negative predictive values, and sensitivity and specificity of all 4 CSF measures using the current cutoffs
Head-to-Head Comparison of 8 Plasma Amyloid-β 42 40 Assays in Alzheimer . . . In BioFINDER, CSF Aβ42 40 was used as the outcome in the main analysis We also performed a sensitivity analysis with Aβ-PET and CSF Aβ42 40 measured with the Euroimmun assay as outcomes to ensure that the results were not biased by the use of the same antibodies in the CSF and plasma for the Elecsys Aβ42 40 assays
The cerebrospinal fluid biomarker ratio Aβ42 40 identifies amyloid . . . Limitations include a small sample size, use of a pre-analytical protocol not in accordance with the Elecsys CSF immunoassay method sheets, and the lack of a pre-defined cut-off for Aβ42 40 Point estimates for sensitivity and specificity of CSF biomarkers and biomarker ratios versus amyloid PET were 0 93 and 0 57 for Aβ42, 0 96 and 0 69 for
CSF and blood biomarkers for the diagnosis of Alzheimers disease: a . . . Three core CSF biomarkers for the diagnosis of Alzheimer's disease (Aβ42, T-tau, and P-tau) have been assessed in numerous studies, and several other Alzheimer's disease markers are emerging in the literature 8 High diagnostic accuracy of these biomarkers has been shown for Alzheimer's disease, with sensitivity and specificity reaching 85
Cerebrospinal Fluid (CSF) Assay of Aβ42, phosphorylated Tau (P-tau) and . . . Based on the NDDL’s and international experience, CSF biomarkers are concordant with amyloid PET imaging and offer approximately ~90% sensitivity and specificity for Alzheimer’s Disease The test is intended to provide support for the clinical diagnosis of AD in patients presenting with cognition deficiency
Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer’s . . . The arrival of new disease-modifying treatments for Alzheimer’s disease (AD) requires the identification of subjects at risk in a simple, inexpensive, and non-invasive way Both plasma and CSF Aβ40, Aβ42, and p-tau181 have been evaluated in a group of 208 cognitively unimpaired subjects with a 30 3% of ApoE4 carriers (95%CI 0 78
CSF Aβ1–42 – an excellent but complicated Alzheimers biomarker – a . . . The 42 amino acid form of amyloid β peptide (Aβ 1–42) in cerebrospinal fluid (CSF) is widely accepted as a key biomarker for Alzheimer's disease (AD) together with the total tau (T-tau) and phosphorylated tau (P-tau) protein [1] The decrease of Aβ 1–42 concentrations in CSF reflects its deposition in amyloid plaques in the brain [2], that is one of the hallmarks of the disease
High Cerebrospinal Fluid Tau and Low Amyloid β42 Levels in the Clinical . . . Relationship of apolipoprotein E (Apo E) genotype to levels of amyloid β protein ending at amino acid 42 (Αβ42) in cerebrospinal fluid of patients with Alzheimer disease (AD group) and normal control subjects (NC group) Levels of Aβ42 are given by Apo E ϵ4 allele copy number Boxes indicate 25th to 75th percentiles of subjects; lines within boxes, the median values; whiskers, range from